Odonate Therapeutics (ODTC)
$50,000.00
$49,998.50
(3,333,233.33%)
As on 11-Jun-2026 09:30EDT
Market cap
$53 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
7.3
P/B Ratio
0.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.2
-
Debt to Equity
0
-
Book Value
$98291.8
-
EPS
$6659.1
-
Face value
--
-
Shares outstanding
356
9 Years Aggregate
CFO
$-369.81 Mln
EBITDA
$-418.06 Mln
Net Profit
$-378.07 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
| -- | -- | -- | -- | 140.4 | 46.0 | -- |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
| -93.0 | -40.8 | 130.5 | -43.5 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
50,000.0 | 53.4 | 0.0 | 7.3 | -- | 7 | 7.3 | 0.5 |
| 354.9 | 188,671.2 | 37,238.0 | 7,800.0 | 29.1 | 82.9 | 24.3 | 20.5 | |
| 57.1 | 116,663.5 | 48,482.0 | 7,275.0 | 21.6 | 37.7 | 16 | 5.8 | |
| 224.1 | 52,427.0 | 250,549.0 | 1,559.0 | 0.9 | -- | 34.1 | 16.1 | |
| 125.5 | 160,361.2 | 29,734.0 | 9,216.0 | 39.5 | 40.9 | 17.6 | 6.8 | |
| 789.5 | 94,623.4 | 403,430.0 | 4,762.0 | 1.6 | -246.4 | 20.5 | 5.0 | |
| 120.0 | 298,256.0 | 65,593.0 | 8,935.0 | 24.7 | 18.3 | 34 | 6.4 | |
| 153.5 | 293,693.5 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 22.1 | 7.6 | |
| 26.2 | 149,154.5 | 63,315.0 | 7,491.0 | 16.7 | 8.1 | 20 | 1.6 | |
| 80.3 | 33,358.0 | 9,509.0 | 2,643.0 | 37.3 | 61.2 | 13 | 10.3 |
Shareholding Pattern
View DetailsAbout Odonate Therapeutics (ODTC)
Odonate, Inc., has no significant operations. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
-
Chairman & CEO
Mr. Kevin C. Tang
-
Chairman & CEO
Mr. Kevin C. Tang
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Odonate Therapeutics (ODTC)
What is the current share price of Odonate Therapeutics (ODTC) Today?
The share price of Odonate Therapeutics (ODTC) is $50,000.00 (NASDAQ) as of 11-Jun-2026 09:30 EDT. Odonate Therapeutics (ODTC) has given a return of 140.37% in the last 3 years.
What is the current PB & PE ratio of Odonate Therapeutics (ODTC)?
The P/E ratio of Odonate Therapeutics (ODTC) is 7.29 times as on 05-Jun-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
|
2020
|
0.00
|
0.00
|
|
2019
|
0.00
|
0.00
|
What is the 52 Week High and Low of Odonate Therapeutics (ODTC)?
The 52-week high and low of Odonate Therapeutics (ODTC) are Rs 50,000.00 and Rs 50,000.00 as of 14-Jun-2026.
What is the market cap of Odonate Therapeutics (ODTC)?
Odonate Therapeutics (ODTC) has a market capitalisation of $ 53 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Odonate Therapeutics (ODTC)?
Before investing in Odonate Therapeutics (ODTC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.